The NIH's decision comes after concerns over managing sub-award payments to foreign researchers. This policy shift could jeopardize thousands of research projects that rely on global partnerships, especially in the realm of life-saving medical studies. Officials claim the intention is to enhance accountability in grant funding, although the consequences could reverberate across the scientific community.
In a significant blow to global health collaboration, a recent policy from the National Institutes of Health (NIH) has barred U.S.-based scientists from using federal grant funds to pay foreign collaborators. This shift threatens critical research projects, including one aimed at prolonging lives for women facing recurrence of the most common type of breast cancer.
Breast cancer that is fueled by estrogen can have life-threatening effects even after a decade of remission, with many patients at risk. The research, which has been conducted in collaboration with researchers in Denmark, may now be forced to terminate due to the new policy prohibiting financial support for foreign partners.
The NIH asserts that this decision was taken to address internal discrepancies in tracking sub-award payments, an issue highlighted in multiple reports from the Government Accountability Office. An NIH official emphasized that heightened oversight is crucial, claiming that the lack of visibility in funding practices has become untenable. Despite these claims, many in the health and research fields are concerned that this policy could hinder vital cancer research efforts and global scientific collaboration, ultimately impeding advancements that would benefit patient outcomes in the U.S. and beyond.
Federal health authorities are under pressure to reevaluate this directive to mitigate risks to international research partnerships, essential for addressing ongoing health challenges. The ramifications of the NIH's move underscore the growing tensions between governmental funding practices and the collaborative spirit of global scientific inquiry.
In a significant blow to global health collaboration, a recent policy from the National Institutes of Health (NIH) has barred U.S.-based scientists from using federal grant funds to pay foreign collaborators. This shift threatens critical research projects, including one aimed at prolonging lives for women facing recurrence of the most common type of breast cancer.
Breast cancer that is fueled by estrogen can have life-threatening effects even after a decade of remission, with many patients at risk. The research, which has been conducted in collaboration with researchers in Denmark, may now be forced to terminate due to the new policy prohibiting financial support for foreign partners.
The NIH asserts that this decision was taken to address internal discrepancies in tracking sub-award payments, an issue highlighted in multiple reports from the Government Accountability Office. An NIH official emphasized that heightened oversight is crucial, claiming that the lack of visibility in funding practices has become untenable. Despite these claims, many in the health and research fields are concerned that this policy could hinder vital cancer research efforts and global scientific collaboration, ultimately impeding advancements that would benefit patient outcomes in the U.S. and beyond.
Federal health authorities are under pressure to reevaluate this directive to mitigate risks to international research partnerships, essential for addressing ongoing health challenges. The ramifications of the NIH's move underscore the growing tensions between governmental funding practices and the collaborative spirit of global scientific inquiry.
